Company / SG&A Expense
TherapeuticsMD, Inc. SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$8.9M
FY2024
5-year range
$8.9M / $116.0M
FY2020-FY2024
Trend
-84.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $9M in FY2024 to $116M in FY2020.
Based on SEC 10-K filings.
$9M in FY2024 with a 5-year CAGR of -31.2%.
Improved from $81M to $9M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -47.2%
- 5-Year CAGR
- -31.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -31.2%, indicating a declining trend.
- In FY2024, sg&a expense decreased 84.3% year-over-year.
- Peak sg&a expense was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $8.9M | -84.3% |
| FY2023 | $56.7M | -29.8% |
| FY2022 | $80.7M | +33.5% |
| FY2021 | $60.5M | -47.8% |
| FY2020 | $116.0M | +101.0% |
| FY2019 | $57.7M | +12.4% |
| FY2018 | $51.3M | +78.8% |
| FY2017 | $28.7M | +29.8% |
| FY2016 | $22.1M | +16.4% |
| FY2015 | $19.0M | +35.1% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026